Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer. - Wikidata - awgldk - TriplyDB

Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer.

Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer.

http://www.wikidata.org/entity/Q36615636

about

Epigenetic changes of DNA repair genes in cancer Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy Fancf-deficient mice are prone to develop ovarian tumours Promoter Hypermethylation of FANCF and Susceptibility and Prognosis of Epithelial Ovarian Cancer Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease.DNA methyltransferases, DNA damage repair, and cancer Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer.Gene silencing of FANCF potentiates the sensitivity to mitoxantrone through activation of JNK and p38 signal pathways in breast cancer cells Genetic variants in fanconi anemia pathway genes BRCA2 and FANCA predict melanoma survival.Translational application of epigenetic alterations: ovarian cancer as a model.RNA interference-mediated FANCF silencing sensitizes OVCAR3 ovarian cancer cells to adriamycin through increased adriamycin-induced apoptosis dependent on JNK activation.Pharmaco(epi)genomics in ovarian cancer.BRCA and Early Events in the Development of Serous Ovarian Cancer.RNAi-mediated knockdown of FANCF suppresses cell proliferation, migration, invasion, and drug resistance potential of breast cancer cells.Fanconi anaemia: from a monogenic disease to sporadic cancer.Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.Effects of single-dose atorvastatin on interleukin-6, interferon gamma, and myocardial no-reflow in a rabbit model of acute myocardial infarction and reperfusion.Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer.Low incidence of methylation of the promoter region of the FANCF gene in Japanese primary breast cancer.Inhibition of non-homologous end joining in Fanconi Anemia cells results in rescue of survival after interstrand crosslinks but sensitization to replication associated double-strand breaks.Approaches for Identifying Novel Targets in Precision Medicine: Lessons from DNA Repair.

P2860

Q22242858-1C1CFF76-53E9-4088-B5BB-7099AE76C6F4 Q26769604-DE913214-FB1F-4BBD-B2F4-0D7C1A59C291 Q28247935-428D0412-6C6D-42CD-A621-F0546500DEEC Q28269159-38CBAC34-684E-42DE-9B5C-B449E95D8D71 Q30448232-32D39C68-BC9C-4505-8FBD-1BA2CC64FF72 Q34298096-B717A3BC-9B9C-4DFA-88D7-B379CD13A685 Q34305493-CB10AEF5-CE2B-469F-9442-230378F01755 Q34406515-1CDC0111-DB22-412F-A669-09527FBD06C9 Q34899498-C15E5A7B-3CB7-4B9B-A5F3-92AF7ABFFAC3 Q35085782-F0464CD7-478C-4781-AB73-0708E500359B Q36858599-438504D3-2BA6-4494-9159-ABAE05BCFBDC Q37346198-09827C6A-BD4D-4A2D-9E00-636BE42B941F Q37513137-11697FCF-8F15-4803-B82A-9BC6AD8B7942 Q37600026-B79E2618-6D2D-4F65-870B-EE1855C1C9B2 Q37865169-7E01280A-6518-43A4-9774-9E5DB8FAFB03 Q37933098-7356D959-D2D3-4108-96AC-12D6B8E40EA4 Q38699009-4A4DF7DE-0DBF-48F2-80D3-0C8A5E078C48 Q42378380-E90E47CD-DBE8-4435-AD76-640EE6DAF848 Q42461070-AD10DE55-5E1D-4437-9E49-647EF0043696 Q49833942-380659A6-C5DF-4F41-AE3D-6AE1081155A0 Q51800946-6D930260-E0B3-4CE9-AD21-E6C27A06C7AD

P2860

Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer.

http://www.wikidata.org/entity/Q36615636

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer.

@ast

Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer.

@en

type

label

Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer.

@ast

Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer.

@en

prefLabel

Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer.

@ast

Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer.

@en

P1433

Q36615636-E7EE4CC0-30F3-497C-91DA-1FCF60F70E08

P1476

Q36615636-6D0BA29C-8455-4F15-B781-22A58E6B5D93

P2093

Q36615636-1D3E9021-CF40-4507-870B-E9046DDB3208

Q36615636-3AFEBD4D-464A-458C-91DC-4672C08377D6

Q36615636-48305B1E-15CB-474E-96BF-96D41BD62E1F

Q36615636-584153FE-33AB-4A04-AB20-BC914EF8B29F

Q36615636-6CD95824-98F5-4FBC-AC44-5EC1C4E9F60C

Q36615636-822CD416-EF16-456B-A3FB-D42D30191894

Q36615636-85990540-865F-49E6-AB9F-A2159582284C

Q36615636-C6FC5978-EC69-4288-A60F-243D185669A4

Q36615636-DDBA8CF4-3755-4211-9F18-9BF305C4F11B

P2860

Q36615636-10EDBB7A-A57B-4E63-9258-47DB940FA0CB

Q36615636-39881D2A-55D0-4588-8098-230ED1124989

Q36615636-49C025AC-B7C8-47C1-8F4A-B57BE4D54EE8

Q36615636-55833BAB-8A62-4D06-8B8B-32D4E13B7AB5

Q36615636-7AC5450F-30DF-49EE-A3D5-C5718AB472CC

Q36615636-8FE0EF14-9AC1-4726-B176-A8ACEC3EB5A7

Q36615636-AEA7B275-4A48-4995-9FAF-9EB7FDFD9FBF

Q36615636-D5DEBB54-91C7-48AC-8208-A70FF8D552C8

Q36615636-E6687A19-175F-4FEF-872B-237E464A600D

Q36615636-F41FCB39-3192-4738-A062-A394F1C038F5

P2888

Q36615636-BEC0AEDE-8F24-4762-B3CB-9386AE3F358F

P304

Q36615636-95889DC7-A439-4244-8C89-3E4649D4276A

P31

Q36615636-36A1BAD3-D370-4436-8752-37A74A9E8286

P356

Q36615636-B73A4856-A525-4945-B84A-AB1EABC2C773

P407

Q36615636-451F1979-C107-40EC-A14E-A3A82370560B

P433

Q36615636-5A66EA8F-07F6-4F78-855B-866A6BE21C4F

P478

Q36615636-9E26E309-E4BB-4CD3-8A17-C7F9B8520388

P577

Q36615636-CCBAE4AE-0C9F-4643-8D91-78E7BE549602

P5875

Q36615636-C22898B0-E477-4D31-9A40-13289B778088

P698

Q36615636-F62B7B5B-0B77-4CD0-B946-44A5E3225A2C

P921

Q36615636-C735D9F3-A3EC-44AA-BB7A-2B6E6B7F3C75

P932

Q36615636-4C0341D2-D450-4B5F-AE22-BA564144A72B

P356

P1433

British Journal of Cancer

P1476

Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer.

@en

P2093

C Coens

http://www.w3.org/2001/XMLSchema#string

H Wong

http://www.w3.org/2001/XMLSchema#string

J A Green

http://www.w3.org/2001/XMLSchema#string

M van der Burg

http://www.w3.org/2001/XMLSchema#string

N Syed

http://www.w3.org/2001/XMLSchema#string

P Smith

http://www.w3.org/2001/XMLSchema#string

P Szlosarek

http://www.w3.org/2001/XMLSchema#string

S L Lim

http://www.w3.org/2001/XMLSchema#string

T Crook

http://www.w3.org/2001/XMLSchema#string

P2860

Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands

Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors

Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival

Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors

The Fanconi anaemia/BRCA pathway

Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer

Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway

Second-line treatment of ovarian cancer.

Cell cycle-mediated drug resistance: an emerging concept in cancer therapy.

The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients.

P2888

P304

1452-1456

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6604325

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P577

2008-04-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232757493

http://www.w3.org/2001/XMLSchema#string

P698

18414472

http://www.w3.org/2001/XMLSchema#string

P921

P932

2361708

http://www.w3.org/2001/XMLSchema#string